SpringWorks Therapeutics Inc
1 day chart
SpringWorks Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing life-changing medicines for patients living with severe rare diseases and cancer. It has a differentiated targeted oncology pipeline spanning solid tumors and hematological cancers, including two late-stage clinical trials in rare tumor types as well as several programs addressing highly prevalent, genetically defined cancers. Its product candidate, nirogacestat, is an oral, small molecule gamma secretase inhibitor (GSI), in development as a monotherapy for the treatment of desmoid tumors, a rare and often debilitating and disfiguring soft tissue tumor. Its second product candidate is mirdametinib, an oral, small molecule MEK inhibitor in development for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN), a rare tumor of the peripheral nerve sheath that causes pain and disfigurement.
Buy US stocks in Australia starting with SWTX. Open an account and start investing today!
To do so follow these steps:
- Sign up in minutes, all you need is some I.D.
- Choose Stake Wall St
- Deposit directly into your Stake wallet and you're ready to invest in SWTX
This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.